19 reports

  • Sleep Aid Value Sales (USD million rsp) 2011/2016 and % CAGR 2011-2016 by Region
  • Western Europe: Sleep Aid Value Sales (USD million rsp) 2016 and % CAGR 2016-2021
  • Sleep Aid
  • World
  • Demand
  • Bayer AG
  • Pfizer Inc.
  • 5.2.2.1 EROSION IN BRANDED PRESCRIPTION SLEEP AID SALES DUE TO GROWING ADOPTION OF GENERICS
  • U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
  • Sleep Aid
  • United States
  • Company
  • Market Size
  • Merck & Co., Inc.
  • COMPETITIVE LANDSCAPE
  • PROSPECTS
  • Sleep Aid
  • Saudi Arabia
  • Demand
  • Cigalah Group
  • GlaxoSmithKline plc

Adverse effects of sleep aid medication\n##. ##. ##. ##.

  • OTC
  • Sleep Aid
  • World
  • Market Size

The sleeping aid products industry has witnessed huge growth in the recent years.

  • OTC
  • Sleep Aid
  • World
  • Market Size

On the basis of sleep disorder, the sleep aids market comprises insomnia, sleep apnea, restless legs syndrome, narcolepsy and sleep walking.

  • OTC
  • Sleep Aid
  • World
  • Market Size
  • PROSPECTS

However, over the review period Vemedia started to expand its portfolio with Sleepzz, a sleep aid especially targeted towards children.

  • OTC
  • Sleep Aid
  • Netherlands
  • Demand
  • HEADLINES

As players aim to maintain a strong image of their recently available and marketed sleep aid products, they will most probably not expand sales channels any time soon.

  • Allergy Drug
  • Sleep Aid
  • Norway
  • Demand
  • Orkla Group
  • COMPETITIVE LANDSCAPE

The Portuguese tend to prefer herbal/ natural sleep aid products like Valdispert and Arkocapsulas as they are perceived as having fewer side-effects and, more importantly, are not addictive.

  • Sleep Aid
  • Portugal
  • Herbalife Ltd.
  • Pfizer Inc.
  • Unipessoal, Lda
  • PROSPECTS
  • HEADLINES

Also in 2017, Bayer México SA de CV launched the new product Flanax Nocto combining naproxen as an analgesic and diphenhydramine as a sleeping aid.

  • Sleep Aid
  • Mexico
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Sanofi S.A.
  • HEADLINES

Pharma Nord Kft, meanwhile, recently introduced the first sleep aid available in Hungary that does not contain the typical herbal extracts found in these products; instead, its active ingredient is melatonin.

  • OTC
  • Sleep Aid
  • Hungary
  • Demand
  • Sanofi S.A.

Sleeping Aids Market

4773 5250 4057

Higher stress levels amongst people in developed nations and fast changing life styles in the developing nations are expected to remain key growth drivers for the sleeping aid products during the period of study and are also expected to intensify as population with higher stress le

  • OTC
  • Sleep Aid
  • Market Size
  • summarizes the minor therapeutic classes in the insomnia market.
  • 6.3 OTHER THERAPEUTIC CLASSES

FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose.

  • Sleep Aid
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.

THEREFORE, PRODUCTS RELATED TO AIDING SLEEP ARE USUALLY AVOIDED, AND NATURAL TREATMENTS SUCH AS EATING WELL AND EXERCISING ARE USUALLY FAVOURED.

  • Sleep Aid
  • United Arab Emirates
  • GlaxoSmithKline plc
  • NBTY, Inc.
  • Vitabiotics Ltd
  • 5.3 OTHER THERAPEUTIC CLASSES
  • summarizes the minor therapeutic classes in the insomnia market.

FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose.

  • Sleep Aid
  • Europe
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Neurim Pharmaceuticals Ltd
  • PROSPECTS

Pharmaco (NZ) Ltd, with its non-herbal/ traditional sleep aid Unisom, ranked fourth in 2016 with a value share of ##%.

  • OTC
  • Sleep Aid
  • New Zealand
  • Demand
  • Vitaco Health NZ Ltd
  • SUMMARY OF MINOR THERAPEUTIC CLASSES, 2015
  • 5.3 OTHER THERAPEUTIC CLASSES

FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose.

  • Sleep Aid
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Neurim Pharmaceuticals Ltd
  • Takeda Pharmaceutical Company Limited
  • SUMMARY OF MINOR THERAPEUTIC CLASSES, 2015
  • summarizes the minor therapeutic classes in the insomnia market.

FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose.

  • Sleep Aid
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Neurim Pharmaceuticals Ltd
  • Takeda Pharmaceutical Company Limited
  • 5.1 BIBLIOGRAPHY

FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose.

  • Sleep Aid
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Neurim Pharmaceuticals Ltd
  • Pernix Therapeutics Holdings, Inc.